From the Guidelines

Stem Cell Therapy is not superior for treating Hip Osteoarthritis (Degenerative Joint Disease).

The 2019 American College of Rheumatology guideline strongly recommends against the use of stem cell injections in patients with hip OA due to concerns about heterogeneity and lack of standardization in available preparations and techniques 1.
There is a lack of evidence to support the use of stem cell therapy for hip OA, and existing recommendations are based on expert consensus rather than high-quality research evidence.
Other treatments, such as NSAIDs, paracetamol, and exercise, have more established evidence for efficacy in hip OA, although their effectiveness may vary depending on individual patient factors 1.
The EULAR recommendations for hip OA highlight the need for more research on the effectiveness of different treatments, including stem cell therapy, and emphasize the importance of considering the potential risks and benefits of each treatment option 1.

NSAIDs: effective for pain relief in hip OA, but may have gastrointestinal side effects 1.
Paracetamol: may be effective for pain relief, but evidence is limited and inconclusive 1.
Exercise: recommended as a core non-pharmacological treatment for hip OA, although evidence is largely based on studies of knee OA 1.
SYSADOA (glucosamine sulphate, chondroitin sulphate, etc.): may have symptomatic benefits, but evidence is limited and inconclusive, and effect sizes are generally small 1.

From the Research

Stem cell therapies have emerged as a promising alternative for treating hip osteoarthritis, offering potential disease-modifying benefits through immunomodulatory actions, growth factor secretion, and chondrogenic capabilities 2.
Adipose-derived mesenchymal stem cells (ADMSCs) have shown promise in clinical trials for osteoarthritis treatment, offering potential pain relief and functional improvement 2.

Intra-articular mesenchymal stem cell (MSC) therapy has been reported to be safe, with generally positive clinical outcomes, although the overall quality of the literature is poor and heterogeneity limits firm conclusions regarding efficacy 3.
Bone marrow-derived stem cell (BM-MSC) therapy has been found to improve clinical outcomes in patients with hip osteoarthritis, with reduction in pain and increase in functional ability across studies 4.
Mesenchymal stem cells (MSCs) have been shown to migrate to injured sites, inhibit pro-inflammatory pathways, and promote tissue repair, providing a potential therapeutic approach for osteoarthritis 5.

Clinical trials have displayed significant improvement in both pain and joint function, inflammatory cell reduction within a joint, and articular cartilage growth, as well as patient safety 5.
Intra-articular MSC infiltrations have demonstrated promise as an effective and safe therapeutic intervention for managing hip osteoarthritis, offering pain relief and functional enhancements 6.
Studies have reported favorable improvements in functional scores, pain relief, and cartilage repair/radiographic findings, with minimal reported adverse events 6.

Further research is required to establish the long-term efficacy of stem cell therapies, identify optimal stem cell types, and develop standardized protocols 2.
High-quality studies with larger sample sizes and longer follow-up periods are needed to confirm the efficacy and safety of stem cell therapies for hip osteoarthritis 6.
Future investigations should address optimal MSC utilization, long-term outcomes, and potential complications to ensure the success of MSC-based therapies for hip osteoarthritis management 6.